Yes, I think this is actually positive for Neuren. It seems to me Acadia has been trying to downplay the importance of Trofinitide & NNZ-2591 to their future plans, possibly because they want to maintain a strong negotiating position with Neuren regarding any future deals. Hence their investment in the prader willi trial and continuing to try extending their existing drug (despite multiple failures). I don't think Acadia wants to look like a one trick pony entirely dependent upon Neuren's licensed drugs. However, with this failure, this is increasingly what they are.
Their bluffs are being called.
I suspect they may soon have to suck it up and announce they're putting significant efforts into developing NNZ-2591 for Fragile-X and Retts - as their best remaining options for the future of their business.
I wouldn't be surprised if we hear about another failure soon on their current Ph 3 trial for prader-willi hyperphagia. and I wonder how the Alzheimers Disease Psychosis trial is going too?
- Forums
- ASX - By Stock
- Acadia
Yes, I think this is actually positive for Neuren. It seems to...
-
- There are more pages in this discussion • 298 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.86 |
Change
0.560(2.90%) |
Mkt cap ! $2.538B |
Open | High | Low | Value | Volume |
$19.80 | $20.00 | $19.40 | $3.777M | 191.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1060 | $19.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.87 | 209 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1060 | 19.830 |
8 | 6809 | 19.790 |
1 | 2736 | 19.740 |
1 | 1108 | 19.710 |
3 | 1623 | 19.700 |
Price($) | Vol. | No. |
---|---|---|
19.890 | 708 | 2 |
19.900 | 1450 | 1 |
19.910 | 4224 | 3 |
19.920 | 915 | 1 |
19.950 | 434 | 1 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
NEU (ASX) Chart |